Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gennex Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.12.
Gennex Laboratories's long-term debt to total assets ratio
increased
from Mar. 2025 (0.07) to Mar. 2026 (0.12).
It may suggest that Gennex Laboratories is progressively becoming more dependent on debt to grow their business.
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Gennex Laboratories LT-Debt-to-Total-Asset Related Terms
Gennex Laboratories LT-Debt-to-Total-Asset Historical Data
* Premium members only.
The historical data trend for Gennex Laboratories's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gennex Laboratories (BOM:531739) has a LT-Debt-to-Total-Asset of 0.12 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gennex Laboratories and its competitors.
Is Gennex Laboratories' LT-Debt-to-Total-Asset too high?
Gennex Laboratories' current LT-Debt-to-Total-Asset is 0.12. Overall, Gennex Laboratories has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gennex Laboratories' LT-Debt-to-Total-Asset compare to ZTS?
Gennex Laboratories' LT-Debt-to-Total-Asset of 0.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Gennex Laboratories and its competitors. Gennex Laboratories's current LT-Debt-to-Total-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gennex Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Gennex Laboratories (BOM:531739) is currently considered Possible Value Trap. The stock's GF Value™ is ₹15.57, compared to a current price of ₹8.86 — trading 43.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.12. Gennex Laboratories' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Gennex Laboratories (BOM:531739), the current LT-Debt-to-Total-Asset is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gennex Laboratories (BOM:531739) Overvalued in 2026?
Based on GuruFocus' analysis, Gennex Laboratories stock appears to be undervalued.
The current stock price of ₹8.86 is trading 43.1% below its estimated GF Value™ of ₹15.57.
GuruFocus considers Gennex Laboratories to be Possible Value Trap.
Key valuation signals for BOM:531739:
LT-Debt-to-Total-Asset: 0.12
GF Value™: ₹15.57 vs. price of ₹8.86 (43.1% below fair value)
No single metric tells the full story. See the BOM:531739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gennex Laboratories Ltd is engaged in the manufacturing of bulk drugs, and intermediates, Biotech Products. Geographically, the group has a business presence in Bangladesh, Egypt, Germany, Guatemala, Iran, Israel and other countries. Its products include Guaifenesin, Methocarbamol, Fluconazole and Phenazopyridine, among others.
77GF Score
Get the complete analysis for BOM:531739
LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531739 has been successfully added to your 
